A Phase 1 Study of ARV-393 for People With Non-Hodgkin's Lymphoma

Full Title

A Phase 1 First in Human Study of ARV-393 in Adult Participants with Advanced Non-Hodgkin’s Lymphoma

Purpose

Researchers want to find the best dose of ARV-393 to use in people with non-Hodgkin lymphoma. The people in this study have NHL that keeps growing or came back after treatment.

ARV-393 targets and breaks down a protein called BCL6. This protein is found in cancer cells and plays a role in their growth and survival. By breaking down BCL6, ARV-393 may help slow or stop the growth of your cancer. It is taken orally (by mouth).

Contact

For more information and to see if you can join this study, please call Dr. Andrew Zelenetz’s office at 646-608-3728.